Current Opinion in Rheumatology

Papers
(The TQCC of Current Opinion in Rheumatology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
COVID-19 and autoimmune diseases329
The role of diet in hyperuricemia and gout59
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate53
Recent advances in targeted drug delivery for treatment of osteoarthritis50
Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases42
Racial, ethnic, and healthcare disparities in rheumatoid arthritis41
Antirheumatic medications in pregnancy and breastfeeding40
Management of systemic sclerosis: the first five years40
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications40
Management issues in rheumatoid arthritis-associated interstitial lung disease38
Osteoporosis and fractures in rheumatoid arthritis37
The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update37
Preclinical rheumatoid arthritis and rheumatoid arthritis prevention36
Benefits and promotion of physical activity in rheumatoid arthritis34
Double-negative T cells in autoimmune diseases34
COVID-19 and rheumatoid arthritis34
Systemic sclerosis pathogenesis: contribution of recent advances in genetics30
The association of Behçet's syndrome with HLA-B51 as understood in 202129
Telerheumatology: before, during, and after a global pandemic29
Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers28
Cellular aspects of the pathogenesis of lupus nephritis28
Treatment for systemic sclerosis-associated interstitial lung disease28
Inflammation in osteoarthritis: the latest progress and ongoing challenges23
Update on noninfectious uveitis in children and its treatment22
Role of adipose tissues in osteoarthritis22
Recent advances in the diagnosis and management of giant cell arteritis22
Treatment of cutaneous lupus erythematosus: current approaches and future strategies22
Lyme disease: diagnosis and treatment22
New classification criteria for systemic lupus erythematosus22
Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis22
Interstitial lung disease throughout the rheumatoid arthritis disease course21
Lymphocyte immunophenotyping in inflammatory myositis: a review21
The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis21
Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy20
Scleroderma epidemiology update20
New galaxies in the universe of shared decision-making and rheumatoid arthritis20
Inhalants other than personal cigarette smoking and risk for developing rheumatoid arthritis19
Treatment of immune checkpoint inhibitor-induced inflammatory arthritis19
B cells in systemic lupus erythematosus19
Osteoporosis epidemiology using international cohorts18
Update on antimalarials and systemic lupus erythematosus18
Update on gout management: what is old and what is new17
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology17
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights17
Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis16
Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells16
Nonimmune mechanisms in idiopathic inflammatory myopathies16
Physical therapy in axial spondyloarthritis: guidelines, evidence and clinical practice16
Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis16
Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis15
Ribosome dysfunction in osteoarthritis15
Therapeutic advances in eosinophilic granulomatosis with polyangiitis14
Pathogenesis of inclusion body myositis14
The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?14
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment14
Insights into the molecular landscape of osteoarthritis in human tissues14
Update in familial Mediterranean fever14
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies14
Diagnostic delay in axial spondyloarthritis – a past or current problem?14
Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition13
Posttraumatic osteoarthritis: what have we learned to advance osteoarthritis?13
Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors13
Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit13
Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities?13
Low-dose computed tomography for axial spondyloarthritis: update on use and limitations13
Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update12
Did COVID-19 impact osteoarthritis – clinical perspective?12
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance12
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment12
Polymyositis: does it really exist as a distinct clinical subset?12
Calcinosis in systemic sclerosis12
Spondyloarthritis evolution: what is in your history?11
Cancer and scleroderma: recent insights11
Cutaneous and systemic connections in lupus11
Takayasu arteritis11
Differential diagnosis of necrotizing myopathy11
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis11
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis11
MRI of the sacroiliac joints: what is and what is not sacroiliitis?11
MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis11
0.021048069000244